December 9, 2006 |
A federal appeals court upheld Friday an injunction preventing Apotex Corp. from selling its generic version of Plavix, a blockbuster blood thinner marketed by Bristol-Myers Squibb and Sanofi-Aventis. The U.S. Court of Appeals for the Federal Circuit in Washington upheld the injunction issued in August by the U.S. District Court for the Southern District of New York.
May 11, 2007 |
Bristol-Myers Squibb Co. said Thursday that it would plead guilty to criminal charges to end a U.S. antitrust case arising from a bungled patent settlement over the drug maker's blood thinner Plavix. The New York-based company said it would admit to two counts of providing false statements to a government agency. The maximum fine for the charges is $1 million. Bristol-Myers said the false statements were made by "a former Bristol-Myers Squibb senior executive."
September 4, 2002 |
Bristol-Myers Squibb Co. moved closer to Food and Drug Administration approval of the Abilify schizophrenia drug, which may be the company's next big product. The drug maker said it is in discussions with the FDA, which sent a letter indicating that the product may be approved after certain issues are resolved. The company didn't reveal what concerns the FDA raised in the letter. Bristol-Myers said it expects FDA approval of Abilify this year.
August 9, 2006 |
Sanofi-Aventis and Bristol-Myers Squibb Co. are facing generic competition in the U.S. for their top-selling Plavix blood-thinning pill five years earlier than planned. Apotex Inc., a closely held Canadian maker of generic drugs, said it started shipping cheaper copies Tuesday. Plavix is the world's second-best-selling pill. Sanofi and Bristol-Myers lost a bid Monday in U.S. court to block the sales. At stake for Paris-based Sanofi and New York-based Bristol-Myers is $6.